Compare AstraZeneca plc (AZN) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs EPR Properties — how do they compare? AstraZeneca plc trades at $158.6 (market cap $248.14B), while EPR Properties trades at $60.94 (market cap $4.58B). The key difference: AstraZeneca plc is far larger — about 54.2× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.22%). Which is the better fit depends on your goals.
| AZN | EPR | |
|---|---|---|
Market Cap | $248.14B | $4.58B |
Sector | Health | Real Estate |
52-Week High | $209.48 | $64.32 |
52-Week Low | $147.06 | $48.71 |
Enterprise Value | $275.41B | $8.09B |
Dividend Yield | 2.01% | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
EPR Properties trades at $60.81, up 0.68% on the day, with a bearish technical signal but strong fundamentals including a 91.41% gross margin and recent Q2 2026 FFO beat. The company raised full-year guidance after deploying $440 million in investments at an 8.5% cap rate, signaling growth momentum. Dividend payments remain consistent at $0.31 monthly, supported by a conservative 65% AFFO payout ratio.
Outlook is mixed: analyst consensus is a Buy with a $65.30 target (7% upside), but technicals and some sentiment caution near-term. Key risks include theater exposure and rising interest rates. The stock offers a 6% yield with potential for dividend growth, balancing income and moderate appreciation prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
